What is Ligand Pharmaceuticals's gross unrealized gains?

Ligand Pharmaceuticals (LGND) reported gross unrealized gains of $60.71M in Q1 2026.

How has Ligand Pharmaceuticals's gross unrealized gains changed year-over-year?

Ligand Pharmaceuticals's gross unrealized gains increased by 1667.3% year-over-year, from $3.44M to $60.71M.

What is the long-term trend for Ligand Pharmaceuticals's gross unrealized gains?

Over 5 years (2020 to 2025), Ligand Pharmaceuticals's gross unrealized gains has grown at a 114.6% compound annual growth rate (CAGR), from $1.3M to $59.2M.

Ligand Pharmaceuticals LGND Gross Unrealized Gains

Gross Unrealized Gains at other companies

BridgeBio PharmaBBIO

——

Ionis PharmaceuticalsIONS

——

Halozyme TherapeuticsHALO

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.6B+96.7%

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's gross unrealized gains?: Ligand Pharmaceuticals (LGND) reported gross unrealized gains of $60.71M in Q1 2026.
How has Ligand Pharmaceuticals's gross unrealized gains changed year-over-year?: Ligand Pharmaceuticals's gross unrealized gains increased by 1667.3% year-over-year, from $3.44M to $60.71M.
What is the long-term trend for Ligand Pharmaceuticals's gross unrealized gains?: Over 5 years (2020 to 2025), Ligand Pharmaceuticals's gross unrealized gains has grown at a 114.6% compound annual growth rate (CAGR), from $1.3M to $59.2M.